Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat - Migraine Induction in People With Migraine
NCT05750446Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of riociguat in migraine without aura (2 arms), sponsored by Dansk Hovedpinecenter. Primary endpoint: Incidence of migraine attacks at 12 hours. Started Jun 2023; status: completed.
02
Drugs
riociguat
03
Conditions
migraine without aura
Beyond the preview
Go deeper on NCT05750446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750446.